ReviewGenomics, proteomics & bioinformatics2003
Molecular advances in severe acute respiratory syndrome-associated coronavirus (SARS-CoV).
Review in Genomics, proteomics & bioinformatics, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- A stable subgenomic reporter coronavirus enables transcriptional profiling of bystander cells.The Journal of general virology · 2026Article
- The direct and indirect effects of bioactive compounds against coronavirus.Food frontiers · 2022Review
- Introduction on Coronavirus Disease (COVID-19) Pandemic: The Global Challenge.Advances in experimental medicine and biology · 2021Article
- Stacked-autoencoder-based model for COVID-19 diagnosis on CT images.Applied intelligence (Dordrecht, Netherlands) · 2021Article
- Clinical Symptoms and Types of Samples Are Critical Factors for the Molecular Diagnosis of Symptomatic COVID-19 Patients: A Systematic Literature Review.International journal of microbiology · 2021Review
- Lessons from Epidemics, Pandemics, and Surgery.Journal of the American College of Surgeons · 2020Article
- Molecular characterization, pathogen-host interaction pathway and in silico approaches for vaccine design against COVID-19.Journal of chemical neuroanatomy · 2020Review
- Coronavirus Detection in the Clinical Microbiology Laboratory: Are We Ready for Identifying and Diagnosing a Novel Virus?Clinics in laboratory medicine · 2020Review
- The effects of regional climatic condition on the spread of COVID-19 at global scale.The Science of the total environment · 2020Article
- Pathogenic viruses: Molecular detection and characterization.Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases · 2020Review
- The utility of margin-reflex distance in determining the type of surgical intervention for congenital blepharoptosis.Indian journal of ophthalmology · 2016Observational
- Naturally occurring anti-Escherichia coli protein antibodies in the sera of healthy humans cause analytical interference in a recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay for serodiagnosis of severe acute respiratory syndrome.Clinical and vaccine immunology : CVI · 2007Article
- Preparation and evaluation of anti-SARS coronavirus IgY from yolks of immunized SPF chickens.Journal of virological methods · 2006Article
- Adenovirus-mediated expression of the C-terminal domain of SARS-CoV spike protein is sufficient to induce apoptosis in Vero E6 cells.FEBS letters · 2005Article
- The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper.Journal of global infectious diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The sudden outbreak of severe acute respiratory syndrome (SARS) in 2002 prompted the establishment of a global scientific network subsuming most of the traditional rivalries in the competitive field of virology. Within months of the SARS outbreak, collaborative work revealed the identity of the disastrous pathogen as SARS-associated coronavirus (SARS-CoV). However, although the rapid identification of the agent represented an important breakthrough, our understanding of the deadly virus remains limited. Detailed biological knowledge is crucial for the development of effective countermeasures, diagnostic tests, vaccines and antiviral drugs against the SARS-CoV. This article reviews the present state of molecular knowledge about SARS-CoV, from the aspects of comparative genomics, molecular biology of viral genes, evolution, and epidemiology, and describes the diagnostic tests and the anti-viral drugs derived so far based on the available molecular information.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.